Related Experiment Video
Updated: Mar 15, 2026

Comparing the Effects of Electronic Cigarette Vapor and Cigarette Smoke in a Novel In Vivo Exposure System
Published on: May 24, 2017
Electronic cigarettes for smoking cessation.
Jamie Hartmann-Boyce1, Hayden McRobbie, Chris Bullen
1Nuffield Department of Primary Care Health Sciences, University of Oxford, Radcliffe Observatory Quarter, Woodstock Road, Oxford, UK, OX2 6GG.
Electronic cigarettes (ECs) show promise in helping smokers quit, with higher abstinence rates compared to placebo ECs. However, long-term safety remains unknown, and more research is needed.
Area of Science:
- Public Health
- Addiction Medicine
- Respiratory Medicine
Background:
- Electronic cigarettes (ECs) are increasingly used by smokers seeking to reduce smoking risks.
- Concerns exist regarding the efficacy and safety of ECs for smoking cessation.
- This review updates previous findings on ECs for smoking abstinence.
Purpose of the Study:
- To evaluate the safety and effectiveness of ECs in aiding long-term smoking abstinence.
- To assess the impact of ECs on helping individuals quit smoking.
Main Methods:
- Systematic review and meta-analysis of randomized controlled trials (RCTs) and cohort studies.
- Searched multiple databases (Cochrane, CENTRAL, MEDLINE, Embase, PsycINFO) from 2004 to January 2016.
- Included studies with at least six months follow-up for abstinence and one week for adverse events.
Main Results:
- Two RCTs (662 participants) indicated ECs increased long-term smoking abstinence compared to placebo ECs (RR 2.29, 95% CI 1.05 to 4.96).
- Evidence quality for ECs versus placebo was rated 'low' due to small trial numbers and imprecision.
- No significant difference in abstinence was found between ECs and nicotine patches (RR 1.26, 95% CI 0.68 to 2.34), with 'very low' evidence quality.
Conclusions:
- ECs may aid long-term smoking cessation compared to placebo, but confidence in this finding is low.
- The long-term safety of ECs is currently unknown.
- Further research, including 15 ongoing RCTs, is crucial to clarify efficacy and safety.
More Related Videos
09:30A Microcontroller Operated Device for the Generation of Liquid Extracts from Conventional Cigarette Smoke and Electronic Cigarette Aerosol
Published on: January 18, 2018
08:39Generation of Electronic Cigarette Aerosol by a Third-Generation Machine-Vaping Device: Application to Toxicological Studies
Published on: August 25, 2018
Related Concept Videos
Stimulants
Cocaine can be administered via snorting, injection, or smoking. It primarily functions by blocking the reuptake of dopamine, resulting in a euphoric high characterized by an intense sensation of happiness and...
Drugs Acting on Autonomic Ganglia: Stimulants
Ganglionic stimulants activate NM nicotinic receptors in autonomic ganglia, falling into two categories: nicotine mimetics [e.g., lobeline, dimethylpiperazine, tetramethylammonium] and muscarinic receptor agonists [e.g., muscarine, methacholine]. The first category's action is rapid and blocked by nicotinic receptor antagonists, while the second category's action is delayed and blocked by atropine-like agents. Nicotine, an alkaloid, affects the heart rate by stimulating...
Drug Dependence
CNS Depressants: Alcohol and Nicotine
Inhaled Medications
Antiasthma Drugs: Methylxanthines
Theophylline is thought to inhibit phosphodiesterase enzymes, increasing intracellular levels of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). This rise in cAMP and cGMP concentrations stimulates cardiac function,...